156 related articles for article (PubMed ID: 15870143)
1. Timing of DAS28 in infliximab therapy.
Armstrong DJ; Bruce IN
Rheumatology (Oxford); 2005 Sep; 44(9):1203-4; author reply 1204. PubMed ID: 15870143
[No Abstract] [Full Text] [Related]
2. Shortening infusion times for infliximab administration.
Buch MH; Bryer D; Lindsay S; Rees-Evans B; Fairclough A; Emery P
Rheumatology (Oxford); 2006 Apr; 45(4):485-6. PubMed ID: 16352636
[No Abstract] [Full Text] [Related]
3. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration.
Toki H; Momohara S; Tsukahara S; Ikari K
J Rheumatol; 2008 Sep; 35(9):1896-7; author reply 1897. PubMed ID: 18785300
[No Abstract] [Full Text] [Related]
4. How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
van Vollenhoven RF
Ann Rheum Dis; 2009 Aug; 68(8):1237-9. PubMed ID: 19605741
[No Abstract] [Full Text] [Related]
5. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
Pavelka K; Jarosová K; Suchý D; Senolt L; Chroust K; Dusek L; Vencovský J
Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
[TBL] [Abstract][Full Text] [Related]
6. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
van den Bemt BJ; den Broeder AA; Snijders GF; Hekster YA; van Riel PL; Benraad B; Wolbink GJ; van den Hoogen FH
Ann Rheum Dis; 2008 Dec; 67(12):1697-701. PubMed ID: 18245109
[TBL] [Abstract][Full Text] [Related]
7. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
8. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
Soriano ER; Galarza-Maldonado C; Cardiel MH; Pons-Estel BA; Massardo L; Caballero-Uribe CV; Achurra-Castillo AF; Barile-Fabris LA; Chávez-Corrales J; Díaz-Coto JF; Esteva-Spinetti MH; Guibert-Toledano M; Palazuelos FI; Keiserman MW; Lomonte AV; Mota LM; Pineda Villaseñor C; Alarcón GS;
Rheumatology (Oxford); 2008 Jul; 47(7):1097-9. PubMed ID: 18463144
[No Abstract] [Full Text] [Related]
9. DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.
Vander Cruyssen B; Van Looy S; Wyns B; Westhovens R; Durez P; Van den Bosch F; Veys EM; Mielants H; De Clerck L; Peretz A; Malaise M; Verbruggen L; Vastesaeger N; Geldhof A; Boullart L; De Keyser F
Arthritis Res Ther; 2005; 7(5):R1063-71. PubMed ID: 16207323
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.
Buch MH; Marzo-Ortega H; Bingham SJ; Emery P
Rheumatology (Oxford); 2004 Feb; 43(2):243-4. PubMed ID: 14739466
[No Abstract] [Full Text] [Related]
11. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
Ornetti P; Solau E; Gaudin P; Sibilia J; Berthelot JM; Puechal X; Tavernier C; Maillefert JF;
Ann Rheum Dis; 2005 Sep; 64(9):1379-80. PubMed ID: 16100349
[No Abstract] [Full Text] [Related]
12. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
13. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
Kerkeni S; Marotte H; Miossec P
Muscle Nerve; 2008 Oct; 38(4):1343-5. PubMed ID: 18816604
[No Abstract] [Full Text] [Related]
14. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
Flendrie M; Creemers MC; van Riel PL
Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
[TBL] [Abstract][Full Text] [Related]
15. Reactions to infliximab in patients with rheumatoid arthritis.
Sakellariou GT; Chatzigiannis I
J Rheumatol; 2005 Jul; 32(7):1411-2. PubMed ID: 15996088
[No Abstract] [Full Text] [Related]
16. Is IV infliximab better than IV methylprednisolone for the treatment of patients with RA when methotrexate fails?
Smith MD
Ann Rheum Dis; 2005 Mar; 64(3):512; author reply 512. PubMed ID: 15708914
[No Abstract] [Full Text] [Related]
17. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
[No Abstract] [Full Text] [Related]
18. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE.
van Vollenhoven RF; Klareskog L
Scand J Rheumatol; 2007; 36(6):418-23. PubMed ID: 18092261
[TBL] [Abstract][Full Text] [Related]
19. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
[TBL] [Abstract][Full Text] [Related]
20. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.
Elkayam O; Hawkins PN; Lachmann H; Yaron M; Caspi D
Arthritis Rheum; 2002 Oct; 46(10):2571-3. PubMed ID: 12384913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
